Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Assembly Biosciences (ASMB)
NASDAQ:ASMB
RESEARCH TOOLSreports
ASMB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.05 - $19.93
Previous CloseN/A
Volume7.37K
Average Volume (3M)25.20K
Market Cap
$79.33M
Enterprise Value$2.65M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Mar 06, 2025EPS Estimate
-1.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.14
Shares Outstanding6,356,286
10 Day Avg. Volume29,273
30 Day Avg. Volume25,198
Standard Deviation0.16
R-Squared0.03
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.86
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.03
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.06
Enterprise Value/Ebitda-0.06
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
---
Assembly Biosciences News
PremiumCompany Announcements
Assembly Biosciences Reports Q3 2024 Financials and Strategic Advances
PremiumPre-Earnings
Is ASMB a Buy, Before Earnings?---
Bulls Say, Bears Say
Bulls Say
Financial StabilityNew financing extends cash runway into the first quarter of 2026, providing financial stability for Assembly.
Product DevelopmentABI-5366's pharmacokinetics profile supports once-weekly or potentially once-monthly dosing, offering a more convenient treatment option for HSV.
Strategic InvestmentGilead's latest equity investment, priced at a premium, raises their ownership of Assembly's voting stock from approximately 19.9% to 29.9%.
Bears Say
Clinical Trial RisksKey risks include failed or equivocal trial results, unforeseen safety or tolerability issues, and meaningful delays to expected timelines.
Market SentimentIndustry enthusiasm around Hepatitis B has waned after multiple setbacks, posing a challenge for Assembly's market perception.
Program UncertaintyThere is current uncertainty on the efficacy of Assembly's programs, including ABI-5366, ABI-4334, and ABI-6250, which could affect their advancement towards regulatory approvals.
---
Ownership Overview
48.32% Insiders
5.95% Mutual Funds
40.42% Other Institutional Investors
1.87% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ASMB FAQ
What was Assembly Biosciences’s price range in the past 12 months?
Assembly Biosciences lowest stock price was $11.05 and its highest was $19.93 in the past 12 months.
What is Assembly Biosciences’s market cap?
Assembly Biosciences’s market cap is $79.33M.
When is Assembly Biosciences’s upcoming earnings report date?
Assembly Biosciences’s upcoming earnings report date is Mar 06, 2025 which is in 13 days.
How were Assembly Biosciences’s earnings last quarter?
Assembly Biosciences released its earnings results on Nov 07, 2024. The company reported -$1.51 earnings per share for the quarter, beating the consensus estimate of -$2.303 by $0.793.
Is Assembly Biosciences overvalued?
According to Wall Street analysts Assembly Biosciences’s price is currently Overvalued.
Does Assembly Biosciences pay dividends?
Assembly Biosciences does not currently pay dividends.
What is Assembly Biosciences’s EPS estimate?
Assembly Biosciences’s EPS estimate is -1.8.
How many shares outstanding does Assembly Biosciences have?
Assembly Biosciences has 6,356,286 shares outstanding.
What happened to Assembly Biosciences’s price movement after its last earnings report?
Assembly Biosciences reported an EPS of -$1.51 in its last earnings report, beating expectations of -$2.303. Following the earnings report the stock price went down -4.114%.
Which hedge fund is a major shareholder of Assembly Biosciences?
Currently, no hedge funds are holding shares in ASMB
---
Assembly Biosciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Hedge Fund Trend
Decreased
By 890.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $20.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
14.76%
12-Months-Change
Fundamentals
Return on Equity
-120.51%
Trailing 12-Months
Asset Growth
94.20%
Trailing 12-Months
Company Description
Assembly Biosciences
Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses in two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin on October 7, 2005 and is headquartered in Carmel, IN.
---
ASMB Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Arrowhead Pharmaceuticals
―
Gilead Sciences
―
Ionis Pharmaceuticals
―
Neurocrine
―
Enanta Pharmaceuticals
―
Best Analysts Covering ASMB
1 Year
1 Year Success Rate
3/28 ratings generated profit
1 Year Average Return
-41.15%
assigned a buy rating 5 months ago
Copying Salim Syed's trades and holding each position for 1 Year would result in 10.71% of your transactions generating a profit, with an average return of -41.15% per trade.
---